403 related articles for article (PubMed ID: 32962123)
21. Curcumin inhibits hypoxia-induced epithelial‑mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway.
Cao L; Xiao X; Lei J; Duan W; Ma Q; Li W
Oncol Rep; 2016 Jun; 35(6):3728-34. PubMed ID: 27035865
[TBL] [Abstract][Full Text] [Related]
22. Current trends in Hedgehog signaling pathway inhibition by small molecules.
Ghirga F; Mori M; Infante P
Bioorg Med Chem Lett; 2018 Oct; 28(19):3131-3140. PubMed ID: 30177379
[TBL] [Abstract][Full Text] [Related]
23. ABT-199 inhibits Hedgehog pathway by acting as a competitive inhibitor of oxysterol, rather as a BH3 mimetic.
Wang J; Zhang Y; Huang WJ; Yang J; Tang WG; Huang TM; Tan WF
Acta Pharmacol Sin; 2021 Jun; 42(6):1005-1013. PubMed ID: 32855528
[TBL] [Abstract][Full Text] [Related]
24. Hedgehog signaling pathway inhibitors: an updated patent review (2015-present).
Quaglio D; Infante P; Di Marcotullio L; Botta B; Mori M
Expert Opin Ther Pat; 2020 Apr; 30(4):235-250. PubMed ID: 32070165
[No Abstract] [Full Text] [Related]
25. Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition.
Miyazaki Y; Matsubara S; Ding Q; Tsukasa K; Yoshimitsu M; Kosai K; Takao S
Mol Cancer; 2016 Jun; 15(1):49. PubMed ID: 27349387
[TBL] [Abstract][Full Text] [Related]
26. The interplay of Patched, Smoothened and cholesterol in Hedgehog signaling.
Hu A; Song BL
Curr Opin Cell Biol; 2019 Dec; 61():31-38. PubMed ID: 31369952
[TBL] [Abstract][Full Text] [Related]
27. Targeted inhibition of Hedgehog-GLI signaling by novel acylguanidine derivatives inhibits melanoma cell growth by inducing replication stress and mitotic catastrophe.
Pietrobono S; Santini R; Gagliardi S; Dapporto F; Colecchia D; Chiariello M; Leone C; Valoti M; Manetti F; Petricci E; Taddei M; Stecca B
Cell Death Dis; 2018 Feb; 9(2):142. PubMed ID: 29396391
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo.
Guo J; Gao J; Li Z; Gong Y; Man X; Jin J; Wu H
Cancer Lett; 2013 Oct; 339(2):185-94. PubMed ID: 23791879
[TBL] [Abstract][Full Text] [Related]
29. A New Smoothened Antagonist Bearing the Purine Scaffold Shows Antitumour Activity In Vitro and In Vivo.
Zárate AM; Espinosa-Bustos C; Guerrero S; Fierro A; Oyarzún-Ampuero F; Quest AFG; Di Marcotullio L; Loricchio E; Caimano M; Calcaterra A; González-Quiroz M; Aguirre A; Meléndez J; Salas CO
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445078
[TBL] [Abstract][Full Text] [Related]
30. Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer.
Kumar V; Chaudhary AK; Dong Y; Zhong HA; Mondal G; Lin F; Kumar V; Mahato RI
Sci Rep; 2017 May; 7(1):1665. PubMed ID: 28490735
[TBL] [Abstract][Full Text] [Related]
31. Expression of smoothened protein in colon cancer and its prognostic value for postoperative liver metastasis.
Ding YL; Wang QS; Zhao WM; Xiang L
Asian Pac J Cancer Prev; 2012; 13(8):4001-5. PubMed ID: 23098507
[TBL] [Abstract][Full Text] [Related]
32. Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.
Chen B; Trang V; Lee A; Williams NS; Wilson AN; Epstein EH; Tang JY; Kim J
Mol Cancer Ther; 2016 May; 15(5):866-76. PubMed ID: 26823493
[TBL] [Abstract][Full Text] [Related]
33. Targeting GLI Transcription Factors in Cancer.
Didiasova M; Schaefer L; Wygrecka M
Molecules; 2018 Apr; 23(5):. PubMed ID: 29695137
[TBL] [Abstract][Full Text] [Related]
34. A novel hedgehog inhibitor for the treatment of hematological malignancies.
Lin P; He Y; Chen G; Ma H; Zheng J; Zhang Z; Cao B; Zhang H; Zhang X; Mao X
Anticancer Drugs; 2018 Nov; 29(10):995-1003. PubMed ID: 30106753
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia Accelerates Aggressiveness of Hepatocellular Carcinoma Cells Involving Oxidative Stress, Epithelial-Mesenchymal Transition and Non-Canonical Hedgehog Signaling.
Liu Z; Tu K; Wang Y; Yao B; Li Q; Wang L; Dou C; Liu Q; Zheng X
Cell Physiol Biochem; 2017; 44(5):1856-1868. PubMed ID: 29237157
[TBL] [Abstract][Full Text] [Related]
36. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures.
Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO
Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic inhibition of Hedgehog-GLI signaling in cancer: epithelial, stromal, or stem cell targets?
Ruiz i Altaba A
Cancer Cell; 2008 Oct; 14(4):281-3. PubMed ID: 18835029
[TBL] [Abstract][Full Text] [Related]
38. Regulation of Smoothened Trafficking and Hedgehog Signaling by the SUMO Pathway.
Ma G; Li S; Han Y; Li S; Yue T; Wang B; Jiang J
Dev Cell; 2016 Nov; 39(4):438-451. PubMed ID: 27746045
[TBL] [Abstract][Full Text] [Related]
39. A synthetic combinatorial approach to disabling deviant Hedgehog signaling.
Fan CW; Yarravarapu N; Shi H; Kulak O; Kim J; Chen C; Lum L
Sci Rep; 2018 Jan; 8(1):1133. PubMed ID: 29348431
[TBL] [Abstract][Full Text] [Related]
40. Reduced level of smoothened suppresses intestinal tumorigenesis by down-regulation of Wnt signaling.
Arimura S; Matsunaga A; Kitamura T; Aoki K; Aoki M; Taketo MM
Gastroenterology; 2009 Aug; 137(2):629-38. PubMed ID: 19427313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
